Literature DB >> 21880487

Conformationally constrained analogs of BAY 59-3074 as novel cannabinoid receptor ligands.

Heidi Teng1, Ganesh A Thakur, Alexandros Makriyannis.   

Abstract

To obtain information on the pharmacophoric requirements of the CB1/CB2 partial agonist BAY 59-3074 we have synthesized a series of new conformationally constrained dibenzofuran (4a-d) and dibenzopyran analogs (5). All constrained analogs exhibited reduced binding affinity at both cannabinoid receptor subtypes, suggesting that planar conformations of these ligands are less favored by both receptors. We also found that 4c, 4d, and 5 exhibited 3- to 12-fold selectivity for hCB2 over rCB1 receptors and may serve as new chemotypes for the development of CB2-selective cannabinergics.
Copyright © 2011. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21880487      PMCID: PMC3693451          DOI: 10.1016/j.bmcl.2011.07.017

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  28 in total

1.  Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist.

Authors:  Jean De Vry; Klaus Rüdiger Jentzsch
Journal:  Eur J Pharmacol       Date:  2002-12-20       Impact factor: 4.432

Review 2.  Latest advances in cannabinoid receptor agonists.

Authors:  Ganesh A Thakur; Ritesh Tichkule; Shama Bajaj; Alexandros Makriyannis
Journal:  Expert Opin Ther Pat       Date:  2009-12       Impact factor: 6.674

3.  The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish.

Authors:  Y Gaoni; R Mechoulam
Journal:  J Am Chem Soc       Date:  1971-01-13       Impact factor: 15.419

Review 4.  International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.

Authors:  A C Howlett; F Barth; T I Bonner; G Cabral; P Casellas; W A Devane; C C Felder; M Herkenham; K Mackie; B R Martin; R Mechoulam; R G Pertwee
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

6.  Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes.

Authors:  A C Howlett
Journal:  Mol Pharmacol       Date:  1985-04       Impact factor: 4.436

7.  Determination and characterization of a cannabinoid receptor in rat brain.

Authors:  W A Devane; F A Dysarz; M R Johnson; L S Melvin; A C Howlett
Journal:  Mol Pharmacol       Date:  1988-11       Impact factor: 4.436

8.  Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271.

Authors:  Frank Mauler; Volker Hinz; Karl Heinz Augstein; Marion Fassbender; Ervin Horváth
Journal:  Brain Res       Date:  2003-10-31       Impact factor: 3.252

9.  3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.

Authors:  Jean De Vry; Dirk Denzer; Elke Reissmueller; Maud Eijckenboom; Markus Heil; Heinrich Meier; Frank Mauler
Journal:  J Pharmacol Exp Ther       Date:  2004-05-12       Impact factor: 4.030

Review 10.  BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury.

Authors:  Frank Mauler; Ervin Horváth; Jean De Vry; Rainer Jäger; Thomas Schwarz; Steffen Sandmann; Corinna Weinz; Roland Heinig; Michael Böttcher
Journal:  CNS Drug Rev       Date:  2003
View more
  1 in total

1.  Practical radical cyclizations with arylboronic acids and trifluoroborates.

Authors:  Jonathan W Lockner; Darryl D Dixon; Rune Risgaard; Phil S Baran
Journal:  Org Lett       Date:  2011-09-16       Impact factor: 6.005

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.